Litigation Details for Teva Pharmaceuticals International GmbH v. Eli Lilly and Company (D. Mass. 2017)

✉ Email this page to a colleague

Docket	⤷ Sign Up	Date Filed	2017-10-24
Court	District Court, D. Massachusetts	Date Terminated	2018-09-27
Cause	28:2201 Declaratory Judgment	Assigned To
Jury Demand	Plaintiff	Referred To
Patents	8,586,045
Link to Docket	External link to docket

The biologic drug covered by the patent cited in this case is ⤷ Sign Up .

Subscribe to access the full database, or Sign Up
Date Filed	Document No.	Description	Snippet	Link To Document
0000-00-00				External link to document
2017-10-24	1		least U.S. Patent Nos. 8,586,045; 8,597,649; 9,266,951; 9,340,614; and 9,346,881 (“the Patents-in-Suit”… THE PATENTS-IN-SUIT A. U.S. Patent No. 8,586,045 38. On November…November 19, 2013, United States Patent No. 8,586,045 (“the ’045 patent”), titled “Methods of Using Anti-CGRP…Infringes The Patents-in-Suit. 21. Eli Lilly tracks and follows Teva’s patents related to the… are United States patents in the same family as EP 1957106, including the Patents-in-Suit. EP 1957106	External link to document
2018-09-27	42	Memorandum & Order	infringement of five of the Teva Patents, U.S. Patent Nos. 8,586,045; 8,597,649; 9,266,951; 9,340,614;… Trademark Office (“USPTO”) issued U.S. Patent No. 8,586,045, entitled “Methods of Using Anti-CGRP Antagonist…infringement of those patents, in connection with two of the Teva Patents, U.S. Patent Nos. 9,884,907 and…claimed in a patent or the use of which is claimed in a patent before the expiration of such patent.”). As …several patents that are relevant to this dispute. On November 19, 2013, the United States Patent and Trademark	External link to document
>Date Filed	>Document No.	>Description	>Snippet	>Link To Document